Navigation Links
Can organic cropping systems be as profitable as conventional systems?
Date:4/6/2009

MADISON, WI, April 6, 2009 -- Which is a better strategy, specializing in one crop or diversified cropping? Is conventional cropping more profitable than organic farming? Is it less risky?

To answer these questions, the University of Wisconsin's College of Agriculture and Life Sciences and Michael Fields Agricultural Institute agronomists established the Wisconsin Integrated Cropping Systems Trial (WICST) in 1990. This research is funded by USDA-ARS.

Systems ranging from species-diverse pasture and organic systems to more specialized conventional alfalfa-based forage and corn-based grain systems were compared at two sites in southern Wisconsin from 1993 to 2006.

Crop production analysis was published in the 2008 MarchApril issue of Agronomy Journal while this companion article focuses on the net returns and associated risk exposure of these systems. Full research results from this current study are presented by Chavas et al. in the 2009 MarchApril issue of Agronomy Journal.

"In our study we found that diversified systems were more profitable than monocropping," explains Joshua Posner, University of Wisconsin.

With feed grade premiums the organic systems were more profitable than the Midwestern standards of continuous corn, no-till corn and soybeans, and intensively managed alfalfa.

Rotational grazing of dairy heifers was as profitable as the organic systems. And to our surprise, including risk premiums into the evaluation did not change the ranking of the systems. This study indicates that governmental policy that supports mono-culture systems is outdated and support should be shifted to programs that promote crop rotations and organic farming practices.


'/>"/>

Contact: Sara Uttech
suttech@agronomy.org
608-268-4948
American Society of Agronomy
Source:Eurekalert

0

GOOD

Page: 1

Related biology news :

1. Engineers develop method to disperse chemically modified graphene in organic solvents
2. Controlling cucumber beetles organically
3. British journal publishes inorganic chemistry research of NJIT professor
4. Organic soils continue to acidify despite reduction in acidic deposition
5. Organic plant waste proves effective weed control for citrus trees
6. Global warming is changing organic matter in soil
7. JHU chemists devise self-assembling organic wires
8. UNH receives $380,000 grant to study organic dairy as closed ecosystem
9. Organic corn: Increasing rotation complexity increases yields
10. New organic molecule in space
11. Are organic crops as productive as conventional?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 1Delawares Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spe 50419 2Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2
...archers at MIT recently found an elegant solution ...anics: why water doesn,t soak into soil at an even... fluid flowing downward. , Scientists call these...or their formation has to do with the surface tens... other medium). Knowing how to account for this ph...
...ORD/SOMERVILLE, Mass. -- A new study from the psyc...hen dieters eliminate carbohydrates from their mea...ks than when they reduce calories, but maintain ca... cognition skills returned to normal. , "This stu...immediate impact on cognitive behavior," explains ...
...ANTONIO Douglas Easton, Ph.D., whose internationa...atterns and causes of the BRCA1 and BRCA2 gene mut...ancer, has been selected to receive the inaugural ...tstanding Investigator Award in Breast Cancer Rese... the Cure, recognizes an investigator whose novel ...
Other Biology News:MIT researchers explain mystery of gravity fingers 2Low-carb diets can affect dieters' cognition skills 2Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research 2
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ing RNAi Industry through,Addition of Important an...P, PALO ALTO, Calif., April 9, 2008 Intradigm Co...c RNA interference (RNAi),therapeutics, today anno...ty (IP) covering certain efficacy-enhancing struct...m the University of Massachusetts Medical,School. ...
...ronext Brussels: THR), a biotechnology company foc..., announces today that it has completed,patient en...y purpose of,this study is to evaluate the safety ...nistered intravenously to acute stroke patients,be... stroke., MITI IV (Microplasmin in Treatment of I...
...Nasdaq: DNDN ) today announced that it has comple...ering of 8.0 million shares of its common,stock an... its common,stock. Net proceeds received by Dendre...Markets LLC served as sole placement agent for the...o previously effective shelf,registration statemen...
Other Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2
Rabbit Anti-Human Rab1A Antibody, Unconjugated from Spring Bioscience
Rat Anti-Acetyl Salicylic Acid conjugated Acetyl Salicylic Acid Polyclonal Antibody, Unconjugated from Cell Sciences
Beadlyte® Human IgE Standard from Upstate
...uct Mouse monoclonal [SPM278] to 67kD Laminin Rec...inoma N592 live cells (Human). Reactivity / Speci... other species. Background Information Laminin, ...e, displays multiple biological activities which a...
Biology Products: